National coverage determinations (NCDs) are binding policy decisions made by the Centers for Medicare & Medicaid Services (CMS) that define whether Medicare will pay for a specific medical item or service across the entire country. Their core purpose is to create a single, consistent coverage standard so that a Medicare beneficiary in Texas has the same access to a covered treatment as someone in Maine. Without an NCD, coverage decisions fall to regional Medicare contractors, which can lead to different rules in different parts of the country.
How NCDs Fit Into Medicare Coverage
Medicare only pays for items and services that are “reasonable and necessary” for diagnosing or treating an illness or injury. That phrase is the legal standard behind every coverage decision. An NCD applies that standard at the national level by reviewing clinical evidence and deciding, for one specific treatment or test, whether it meets the bar.
Most Medicare coverage decisions are actually made locally. Regional Medicare Administrative Contractors (MACs) issue local coverage determinations (LCDs) that apply only within their jurisdiction. An NCD overrides any local policy on the same topic. Once CMS issues an NCD, every contractor, appeals judge, and review board in the Medicare system is bound by it. Federal regulations are explicit on this point: an administrative law judge “may not disregard, set aside, or otherwise review” an NCD. A judge can only check whether the NCD was applied correctly to a particular claim.
What NCDs Actually Decide
An NCD can do one of three things. It can approve nationwide coverage for a service, deny coverage nationwide, or set specific conditions under which coverage applies. That third category is where things get interesting, because it lets CMS say “yes, but only if” rather than giving a blanket answer.
For example, CMS issued an NCD for monoclonal antibody treatments targeting amyloid plaques in Alzheimer’s disease. Rather than covering or rejecting these drugs outright, CMS created a layered policy. Drugs approved by the FDA based on a surrogate endpoint (like reducing amyloid in the brain, which is hoped but not yet proven to help patients) are only covered when the patient is enrolled in a qualifying randomized controlled trial. Drugs approved based on direct evidence of clinical benefit, such as measurably slowing cognitive decline, can be covered in broader prospective studies. In both cases, the studies must include patient populations that reflect the diversity of Medicare beneficiaries nationwide. Outside of these approved study frameworks, coverage is explicitly denied.
This kind of conditional NCD gives CMS a way to allow patient access to promising treatments while requiring the generation of real-world evidence about whether those treatments actually help the Medicare population.
Coverage With Evidence Development
The Alzheimer’s drug example illustrates a tool called Coverage with Evidence Development, or CED. Under CED, CMS covers a treatment only when the patient participates in an approved clinical study or registry. The idea is to close evidence gaps: the treatment looks promising enough to offer, but CMS wants more data before committing to permanent, unconditional coverage.
A CED cycle has a built-in endpoint. CMS plans from the start to re-examine the evidence once the required studies are complete. If the new data supports the treatment’s benefit, CMS can reconsider the NCD and remove the study participation requirement, converting conditional coverage into standard coverage. If the data falls short, coverage can be narrowed or withdrawn entirely.
How an NCD Gets Made
NCDs are developed through an evidence-based review process. CMS examines published clinical literature, consults with medical experts when needed, and opens the process to public comment. Anyone can request that CMS open a review of a particular item or service, including manufacturers, physicians, patient advocacy groups, or individual beneficiaries.
The process is deliberate by design. CMS evaluates whether the treatment falls within a Medicare benefit category, whether the clinical evidence supports its effectiveness, and whether the benefits outweigh the harms for the Medicare population specifically. Because Medicare beneficiaries tend to be older and have more complex health profiles than clinical trial participants, CMS often scrutinizes whether study results translate to its population.
The TCET Pathway for New Devices
One longstanding criticism of NCDs is that they can take a long time to finalize, which delays Medicare coverage for new technologies even after the FDA has cleared them. CMS created the Transitional Coverage for Emerging Technologies (TCET) pathway to address this gap for certain medical devices.
TCET is a voluntary program for manufacturers of FDA-designated Breakthrough Devices. The goal is to finalize an NCD within six months after FDA market authorization, a dramatic acceleration compared to the traditional timeline. CMS expects to accept up to five candidates per year.
The pathway works by front-loading the evidence review. Manufacturers are encouraged to submit nominations roughly 12 months before they expect an FDA decision. CMS then conducts an “Evidence Preview,” a focused literature review that identifies the strengths and weaknesses of the available clinical evidence, including any gaps. If gaps exist, the manufacturer develops an Evidence Development Plan that can include traditional clinical trials or “fit-for-purpose” studies using real-world data from Medicare patients.
TCET also coordinates several steps that previously happened independently: confirming the device fits a Medicare benefit category, assigning billing codes, and establishing payment rates. By running these processes in parallel rather than sequentially, the pathway aims to translate FDA approval into actual patient access more quickly.
Why NCDs Matter for Patients
If you’re on Medicare and your doctor recommends a treatment, the presence or absence of an NCD can directly affect whether you pay out of pocket or Medicare covers it. When no NCD exists for a given service, your regional contractor decides, and that decision might differ from the one made in the next state over. An NCD eliminates that variability.
NCDs also shape which treatments are practically available to Medicare patients. A positive NCD signals to hospitals and clinics that they’ll be reimbursed, which makes them more willing to offer the service. A negative NCD, or one that limits coverage to clinical trial participants, effectively restricts access for anyone not enrolled in a qualifying study. For treatments caught in CED requirements, your ability to receive coverage may depend on whether a nearby medical center is participating in an approved study.
Because NCDs are legally binding throughout the appeals process, they also set firm boundaries on what you can challenge. If an NCD says a service isn’t covered, an appeal can only argue that the NCD was misapplied to your specific situation. You cannot argue that the NCD itself is wrong. That distinction matters if you’re considering whether to appeal a denied claim.